BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit

BIOCRYST PHARMACEUTICALS INC

2023-FY EPS reported -$1.18 revenue$331,412,000

ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).
2024 guidance: ORLADEYO revenue $380-$400M; expects operating profit in 2024, positive EPS and cash flow in 2H 2025.
GAAP net loss Q4 $61.7M ($0.31), FY2023 $226.5M ($1.18); non-GAAP net loss Q4 $56.4M ($0.28).
R&D expenses fell to $70.1M Q4 (-4% yoy); SG&A rose to $64.4M Q4 (+28% yoy) on commercial expansion.
Cash $390.8M at Dec 31, 2023; net cash use $8.6M in Q4.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOCRYST PHARMACEUTICALS INC updated its the fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and full year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 26, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-24-000967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.